6665-83-4

Basic information

• Product Name: 6-HYDROXYFLAVONE
• Synonyms: 6-hydroxy-2-phenyl-4H-chroMen-4-one;6-Hydroxyflavone 98%;HYDROXYFLAVONE, 6-;6-HYDROXYFLAVONE;TIMTEC-BB SBB000766;6-hydroxy-2-phenyl-4-benzopyrone;6-Hydroxyflavone,98%;HYDROXYFLAVONE, 6-(RG)
• CAS NO: 6665-83-4
• Molecular Formula: C₁₅H₁₀O₃
• Molecular Weight: 238.24
• EINECS: 229-704-8
• Product Categories: H;Heterocyclic Building Blocks;Inhibitors;Mono-substituted Flavones;Biochemistry;Flavonoids;Benzopyrans;Building Blocks;Heterocyclic Building Blocks;Bioactive Small Molecules;Building Blocks;Cell Biology;Chemical Synthesis
• Mol File: 6665-83-4.mol
• Article Data: 17

Chemical Properties

• Melting Point: 234-236 °C(lit.)
• Boiling Point: 320.83°C (rough estimate)
• Flash Point: 176.3 °C
• Appearance: light yellow crystals
• Density: 1.2653 (rough estimate)
• Vapor Pressure: 1.02E-08mmHg at 25°C
• Refractive Index: 1.5740 (estimate)
• PKA: 8.98±0.40(Predicted)
• BRN: 15827
• CAS DataBase Reference: 6-HYDROXYFLAVONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-HYDROXYFLAVONE(6665-83-4)
• EPA Substance Registry System: 6-HYDROXYFLAVONE(6665-83-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37/39
• WGK Germany: 3
• Hazardous Substances Data: 6665-83-4(Hazardous Substances Data)

Usage

Chemical Properties

light yellow crystals

Uses

anxiolytic

Synthesis Reference(s)

Tetrahedron Letters, 27, p. 2751, 1986 DOI: 10.1016/S0040-4039(00)84634-1

InChI:InChI=1/C15H10O3/c16-11-6-7-14-12(8-11)13(17)9-15(18-14)10-4-2-1-3-5-10/h1-9,16H

Upstream product

• 98-88-4 benzoyl chloride 
• 490-78-8 2,5-Dihydroxyacetophenone 
• 76279-00-0 4-oxo-2-phenylchroman-6-yl acetate 
• 1289081-28-2 6-propionoxyflavanone 
• 3034-04-6 6-methoxyflavanone 
• 4250-77-5 6-hydroxyflavanone 
• 525-82-6 FLAVONE 
• 76323-09-6 2,5-dihydroxydibenzyloxymethane 
• 64-19-7 acetic acid 
• 93-58-3 benzoic acid methyl ester 
• 1218-80-0 6-bromoflavone 
• 51483-92-2 6-bromo-1-benzopyran-4(4H)-one 
• 98-80-6 phenylboronic acid 
• 107139-52-6 [2-(2,5-Bis-benzoyloxy-phenyl)-2-oxo-ethyl]-triphenyl-phosphonium; bromide 

Downstream Products

• 72994-99-1 6-acetoxyflavone 
• 87232-92-6 6-hydroxy-5-formylflavone 
• 139653-14-8 6-(4-chlorobutoxy)-2-phenyl-4H-1-benzopyran-4-one 
• 139653-26-2 6-<(6-chlorohexyl)oxy>flavone 
• 139653-15-9 6-<(8-bromooctyl)oxy>flavone 
• 140439-53-8 6-<(5-cyanopentyl)oxy>flavone 
• 301206-21-3 ethyl 4-[(4-oxo-4H-1-benzopyran-2-phenyl-6-yl)oxy]butyrate 
• 98783-14-3 ethyl 2-[(4-oxo-4H-1-benzopyran-2-phenyl-6-yl)oxy]acetate 
• 586345-75-7 6-[(5-benzyloxy-4-oxo-4H-pyran-2-yl)methoxy]-2-phenyl-4H-[1]benzopyran-4-one 
• 586345-79-1 5-benzyloxy-1-methyl-2{[(4-oxo-2-phenyl-4H-[1]benzopyran-6-yl)oxy]methyl}-1H-pyridin-4-one 
• 26964-24-9 6-methoxyflavone 
• 4311-02-8 6-hydroxy-5-iodo-2-phenyl-chromen-4-one 

Relevant articles and documents

Chromanone compound as well as preparation method and application thereof

The invention discloses a chromanone compound, a preparation method of the chromanone compound and application of the chromanone compound to preparation of medicines for treating or preventing infectious diseases caused by mycobacterium tuberculosis. Specifically, the present invention relates to a compound represented by formula (I), a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the compound of the present invention, where X, Y, R1, R2, R3 and R4 are as described in the specification. The purpose of the present invention is to prepare a novel compound having anti-mycobacterium tuberculosis activity, which can be used as a potential novel drug for overcoming the problems associated with mycobacterium tuberculosis drug resistance.

Design, synthesis, and biological evaluation of novel 4H-chromen-4-one derivatives as antituberculosis agents against multidrug-resistant tuberculosis

A series of 4H-chromen-4-one derivatives obtained by scaffold morphing of the benzofuran compound, TAM16, were tested for antitubercular activity. Compound 8d was active against drug-sensitive and multidrug-resistant tuberculosis. A preliminary druggability evaluation showed that compound 8d displayed favorable mouse and human microsomal stability, low cytotoxicity, and acceptable oral bioavailability. An in vivo study indicated that compound 8d exhibited modest efficacy in an acute mouse model of TB after 3 weeks of treatment. Thus, 8d is a promising antituberculosis lead compound.

Nickel-catalyzed removal of alkene protecting group of phenols, alcohols via chain walking process

An efficient nickel-catalyzed removal of alkene protection group under mild condition with high functional group tolerance through chain walking process has been established. Not only phenolic ethers, but also alcoholic ethers can be tolerated with the retention of stereocenter adjacent to hydroxyl group. The new reaction brings the homoallyl group into a start of new type of protecting group.